In a latest lawsuit launched by the Consumer Financial Protection Bureau (CFPB), a non-bank residential mortgage loan originator has been accused of breaching the Home Mortgage Disclosure Act (HMDA) via inaccurate HMDA data for the year 2020. As per the complaint raised in the U.S. District Court for the Southern District of Florida, it appears that the central issue at hand is the company’s non-compliance with their 2019 agreement with the CFPB, which centered around alleged HMDA mistakes in the past years.
Under HMDA, financial institutions are legally obligated to faithfully maintain and disclose information regarding their residential mortgage lending activity. Failure to comply with the Act not only incurs regulatory action, but may also lead to reputation issues and potentially, legal penalties. For corporate legal teams, this case is a stark reminder of the importance of regulatory compliance, particularly data accuracy and adherence to consent orders.
While it’s not the first time that the CFPB has taken action against repeated infringements, this case underscores the bureau’s determination in cracking down on the alleged ‘repeat offenders’. Comprehensive, routine checks on HMDA compliance and earnest adherence to regulatory orders can help corporations avoid landing in such a crises. Companies must ensure that they own robust compliance programs that are well-equipped to both, handle the complexities of regulatory mandates and minimize the risks of penalties.
A broader interpretation of this lawsuit also points towards an increasingly stringent regulatory environment, positioning data accuracy and regulatory adherence at the core. This development should prompt organizations, especially those within the financial sector, to reassess their compliance measures, enforce rigorous data quality checks and maintain up-to-date documentation.
Further investigation and proceedings on the case will shed more light on CFPB’s decision and its implications for the financial industry. However, it’s safe to say the message is clear – regulatory bodies are not to be taken lightly and their directives must be stringently followed.